An uncommon EGFR exon 25 mutation in a patient with lung adenocarcinoma successfully treated with Afatinib

被引：0
|
作者：
Kunz, J. [1 ,3 ]
Christopoulos, P. [1 ,2 ]
Grosch, H. [1 ]
Kunz, J. [1 ,3 ]
Thomas, M. [1 ,2 ]
机构：
[1] Univ Klinikum Heidelberg, Thoraxklin & Nation Ctr Tumorerkrankungen, Onkol Thoraxtumoren, Heidelberg, Germany
[2] Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany
[3] Univ Klin Heidelberg, Thoraxklin & Nation Ctr Tumorerkrankungen, Diagnost & Intervent, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P404
引用
收藏
页码：109 / 109
页数：1
相关论文
共 50 条
  • [1] Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib A case report
    Cai, Yangyang
    Wang, Xu
    Guo, Ye
    Sun, Chao
    Xu, Yinghui
    Qiu, Shi
    Ma, Kewei
    [J]. MEDICINE, 2019, 98 (01)
  • [2] Patient with metastatic lung adenocarcinoma with the presence of an activating mutation in exon 21 of the EGFR gene treated with Erlotinib
    Kowalski, Dariusz M.
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : G10 - G10
  • [3] Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation
    Urban, Laszlo
    Doczi, Robert
    Vodicska, Barbara
    Tihanyi, Dora
    Horvath, Magdolna
    Kormos, Dora
    Takacs, Istvan
    Papai-Szekely, Zsolt
    Poka-Farkas, Zsuzsanna
    Varkondi, Edit
    Schwab, Richard
    Hegedus, Csilla
    Valyi-Nagy, Istvan
    Petak, Istvan
    [J]. CLINICAL LUNG CANCER, 2021, 22 (01) : E112 - E115
  • [4] Afatinib in Lung Adenocarcinoma Harboring de novo EGFR Exon 20 Insertions
    Costa, M.
    Lewgoy, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S981 - S981
  • [5] Gefitynib in the first line treatment of patient with adenocarcinoma of the lung with EGFR exon 18 mutation
    Zurawski, Bogdan
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2015, 11 : K5 - K7
  • [6] Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib
    Zhu, You-cai
    Du, Kai-qi
    Wang, Wen-xian
    Song, Zheng-bo
    Xu, Chun-wei
    Chen, Gang
    Zhuang, Wu
    Lv, Tang-feng
    Song, Yong
    [J]. LUNG CANCER, 2018, 121 : 101 - 104
  • [7] SIADH developed in a lung adenocarcinoma patient treated with afatinib
    Miyazaki, K.
    Sato, S.
    Kodama, T.
    Satoh, H.
    Hizawa, N.
    [J]. EUROPEAN GERIATRIC MEDICINE, 2014, 5 (06) : 429 - 429
  • [8] Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib
    Hirokawa, Hisanori
    Hirata, Hirokuni
    Azuma, Hayase
    Sugitate, Kei
    Soda, Sayo
    Matsushima, Jun
    Fukushima, Yasutsugu
    [J]. RESPIRATORY MEDICINE CASE REPORTS, 2024, 51
  • [9] Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation
    Li, Jisheng
    Zhu, Liping
    Stebbing, Justin
    Peng, Ling
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (05) : 1436 - 1439
  • [10] Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication
    Wang, Xiao-Fei
    Zhao, Qi-Tao
    Chen, Cheng
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2020, 27 (05) : E535 - E537
12345